Results of a Phase II Trial of NANVURANLAT in Japan Published in Clinical Cancer Research

September 30, 2024
J-Pharma Co., Ltd.

J-Pharma Co. Ltd. announces that the results of the Phase II study of nanvuranlat in Japan have been published in “Clinical Cancer Research” on September 15, 2024.

[Title of Article]
A Phase II Placebo-Controlled Study of the Effect and Safety of Nanvuranlat in Patients with Advanced Biliary Tract Cancers Previously Treated by Systemic Chemotherapy
https://doi.org/10.1158/1078-0432.CCR-24-0461

The results of the Phase II study of nanvuranlat in Japan were presented orally at previous American Society of Clinical Oncology (ASCO) meetings, and details of the study can be found on the Company’s website news below:

American Society of Clinical Oncology Gastrointestinal Cancer Symposium in January 2023
https://www.j-pharma.com/en/archives/1735

American Society of Clinical Oncology Annual Meeting in June 2023
https://www.j-pharma.com/en/archives/1713

[For further information, please contact.]
J-Pharma Co., Ltd.,
Administration Department, Public Relations
TEL: 045-506-1155
FAX: 045-506-1156
Mail: info@j-pharma.com